Figure 2.

Forest plot of vaccine efficacy (VE) for the first episode of acute respiratory syncytial virus (RSV)–associated respiratory illness (ARI) or by seroresponse in the per protocol (PP) population. Assessment was during the surveillance period, starting 14 days after dosing, unless otherwise noted. A, Efficacy according to RSV-associated ARI definition (first episode of RSV-associated ARI symptoms plus RSV detection in respiratory specimen by polymerase chain reaction analysis). B, Efficacy according to seroresponse definition (ie, RSV-associated ARI symptoms plus seroresponse to nonvaccine antigens). CI, confidence interval; ITT, intention to treat; LRTI, lower respiratory tract illness.